Abstract. The effect of thrombin on the release of tissue plasminogen activator from endothelial cells was studied in primary cultures of human umbilical vein endothelial cells. Tissue plasminogen activator concentration in conditioned medium was measured by a two-site radioimmunometric assay. The addition of increasing concentrations (0.01 to 10 U/ml) of thrombin to confluent cultures produced a saturable, dose-dependent increase in the rate of release of tissue plasminogen activator. A sixfold increase in tissue plasminogen activator concentration (from 2 to 12 ng/ml) occurred after the addition of 1 U/ml thrombin (8 X l0-9 M) to cultures containing 5 X 104 cells/cm2. Enhanced release was not observed until 6 h after thrombin addition, reached a maximum rate of 1.3 ng/ml per h between 8 and 16 h, and then declined to 0.52 ng/ml per h after 16 h. The 6-h lag period before increased tPA release was reproducible and independent of thrombin concentration. 
Introduction
Thrombin has been shown to affect the synthesis, release, or activation of a variety of plasma components through its interaction with the vascular endothelium (1) (2) (3) (4) (5) (6) . Two of these demonstrated effects could play a role in the regulation of the fibrinolytic pathway: the activation of protein C (5), which generates an increase in plasma fibrinolytic activity in vivo (7) , and the thrombin-induced decline of intracellular plasminogen activator activity and plasminogen activator release from bovine aortic endothelial cells in culture (4) . This latter effect is quite dramatic, as shown by the suppression of plasminogen activator activity occurring within minutes after the addition of thrombin. Studies performed to determine which of the two immunochemically distinct plasminogen activators released by the bovine endothelial cells (urokinase or tissue plasminogen activator [8] ) was affected by the addition of thrombin demonstrated a decline in the level of urokinase with no significant effect upon tissue plasminogen activator (tPA)' activity (9) .
Primary cultures of human umbilical vein endothelial cells release a single plasminogen activator, which is immunochemically related to tPA (10) . Unlike in the supernatant of bovine endothelial cells, no urokinase is detected in the supernatant of cultured human endothelial cells. The tPA has a molecular weight of 100,000, does not bind to fibrin, and is inactive. It has been suggested that these unusual characteristics result from an association between the tPA and an endothelial cell synthesized inhibitor through a sodium dodecyl sulfate (SDS)-stable bond (10) . This fibrinolytic inhibitor, found in the culture medium of human endothelial cells, is present in excess (10) (11) (12) . The addition of purified human tPA to the endothelial cell conditioned medium resulted in an increase in the molecular weight of this tPA by 40,000 and a disappearance of tPA activity (10) .
Because primary cultures of human endothelial cells do not release urokinase-like plasminogen activators it was of interest to determine whether thrombin would affect plasminogen activator release in human endothelial cells in culture. Using a solid-phase radioimmunometric assay (13) we investigated the effect of thrombin on the release of tPA from primary cultures of human endothelial cells. We show that thrombin induces an increase in the release of tPA in a dose and time dependent manner.
Methods
Materials. Human alpha-thrombin was a gift from Dr. J. W. Fenton (New York Department of Health, Albany, New York) and had a specific activity of 3,642 U/mg thrombin. Diisopropylfluorophosphate (DFP) treated thrombin was prepared by reacting thrombin with 10 mM DFP at pH 7.2 for 1 h at 370C.
Human tPA was a gift from Dr. D. Collen (University of Leuven, Belgium). tPA-Sepharose was prepared with CNBr-activated Sepharose 4B (Pharmacia Fine Chemicals, Piscataway, NJ) and 100 ,g of tPA/ ml of gel. Antisera against tPA were raised in rabbits as described previously (14) . The IgG fractions were isolated by ammonium sulfate precipitation and DEAE-cellulose chromatography (8) .
Plasminogen was prepared from human plasma by affinity chromatography on lysine-Sepharose (Pharmacia Fine Chemicals) as described (15 Cell culture. Endothelial cells were isolated from human umbilical cord veins as previously described (6) and were cultured on six-well tissue culture plates coated with 2 mg/ml calf skin gelatin. Cells were grown to confluence in RPMI-1640 containing 20% fetal bovine serum, 100 U/ml penicillin, and 100 Mg/ml streptomycin. Primary cultures were used exclusively in these studies. Cell density at confluence was -5 X 104 cells/cm2. Experiments were performed on cultures derived from combining the cells obtained from at least four umbilical cords.
Studies were performed by washing confluent cultures twice with RPMI-1640 and incubating the cultures at 37°C in I ml RPMI-1640 containing 5% NuSerum (final serum concentration, 1.25%) and the indicated concentration of thrombin. The conditioned medium was centrifuged at 15,000 g to remove cell debris, made 0.01% with Tween 80, and frozen at -700C until used. Experiments that were to be analyzed by fibrin autography were performed in 0.55 ml serum-free RPMI- To prepare fibrin agar indicator gels (19) , a 2% solution of agarose in water was boiled, cooled to 47°C and mixed with prewarmed PBS containing 140 Ag/ml plasminogen and 0.8 U/ml thrombin. Fibrinogen (10 mg/ml) in PBS (37°C) was added and the mixture was poured onto a glass plate. Final concentrations were 1% agarose, 37 ug/ml plasminogen, 0.2 U/ml thrombin, and 2 mg/ml fibrinogen. The fibrinagar gel was used immediately. After electrophoresis, the SDS gels were soaked in 2.5% Triton X-O00 for 1.5 h to remove the SDS, patted dry with paper towels, and applied to the surface of the fibrin-agar indicator gel. The indicator gel was allowed to develop at 37°C in a moist chamber, and then photographed.
Assay of fibrinolytic activity. tPA activity was assayed on 1251I fibrin-coated multiwell tissue culture dishes (24 wells, 16 mm; Costar, Data Packaging, Cambridge, MA). The standard cell-free assay contained, in 1 ml, 4 ug of human plasminogen, 0.1% gelatin, 0.1 M Tris HCI, pH 8.1, and tPA. The rate of fibrinolysis was determined by measurement of the amount of radioactivity released from the surface of the dish as a function of time. The results were the average of duplicate samples.
tPA inhibitory activity in conditioned medium was measured by the addition of purified tPA to the medium, incubation of the mixture for 30 min at 37°C, and assay for residual tPA on 1251-fibrin plates.
Plasmin is not inhibited by the tPA inhibitor (unpublished observation). Assays were stopped when untreated tPA controls removed 40-50% of the total radioactivity in the well.
Results
The tPA present in the culture medium of human endothelial cells is irreversibly bound to an inhibitor (10) . Because of the possibility that the presence of this inhibitor might compromise the validity of the tPA radioimmunometric assay, the ability of the assay to measure inhibitor-bound tPA as accurately as free tPA was tested (Table I) . 12 ng/ml of purified tPA was added to serial solutions of conditioned medium which had been previously depleted of endothelial cell tPA (10) , and the extent of inhibition was measured by the '25I-fibrin plate assay. Each sample was then assayed for tPA concentration by the radioimmunometric assay and the value was compared with values from control samples containing identical concentrations of tPA in the absence of conditioned medium. Regardless of the fraction of tPA that was inactivated by the inhibitor, the concentration of tPA measured by the assay did not significantly differ from the control samples. The average value determined for all dilutions of conditioned medium was 12.1±0.77 ng/ml. To determine whether the presence of excess free inhibitor altered the assay, 2.5 ng/ml tPA was added to serial dilutions of conditioned medium, all of which completely inhibited tPA activity. All values measured under these conditions were similar to those of control samples (Table I ). The average value was 2.47±0.39 ng/ml.
To establish the optimum culture conditions for this study, cells were treated with 1 U/ml thrombin for 16 h in the presence of serum-free medium or various concentrations of calf serum. The maximum level of tPA in cultures treated in serum-free medium was 6-7 ng/ml although values as low as 4 ng/ml were observed. The addition of as little as 0.01% of tPA in the conditioned medium (Fig. 2) . This increase was first detectable with 0.1 U/ml thrombin (27 ng/ml). Maximum levels of tPA ( 12 ng/ml, a sixfold increase) were observed with 1 U/ml thrombin; thrombin at levels > 1 U/ml did not induce additional increases in tPA levels. Changes in the level of tPA were measured at various times during the 24 h after the addition of 1 U/ml thrombin (Fig. 3) . The release of tPA during the first 6 h was only slightly increased over control values. However, between 6 and 8 h the average rate of release rose to 0.64 ng/ml per h, increased to 1.3 ng/ml per h between 8 and 16 h, and then declined to 0.52 ng/ml per h from 16 to 24 h. The duration of the initial delay was independent of the concentration of thrombin since cultures treated with 0.1, 1, or 10 U/ml demonstrated the same lag period. Thus it appears that stimulation of tPA release by thrombin evolves slowly and is delayed -6 h. When cells were treated with a second dose of I U/ml thrombin at 24 h, either by removal of the original culture medium and addition of fresh medium containing thrombin or by addition of the additional thrombin directly to the existing medium, no secondary enhancement in the rate of tPA release was observed. The increase in tPA concentration between 24 and 48 h in cultures treated with a second dose of thrombin was similar to that in cultures remaining on the original thrombin (not shown).
Experiments were also performed to determine whether enhanced tPA release depended upon the continued presence of thrombin or whether brief exposure was enough to stimulate tPA release. In these studies cultures were treated for 1 h with I U/ml thrombin, washed, and incubated for an additional 24 h in thrombin-free medium. The tPA concentration in the 24 h conditioned medium was 3.6±0.44 ng/ml as compared with 1.9±0.58 ng/ml in untreated cultures. Maximum release of tPA in cultures continuously exposed to thrombin was 13.3±3. were incubated with or without 1
. Enhanced release of tPA was thrombin active site-dependent since the addition of DFP-treated thrombin (1 U/ml) did not * Confluent cultures were incubated in the presence or absence of 1 U/ml thrombin for the specified amount of time, washed twice with methionine-free DMEM, and treated with the methionine-free medium containing 10 4Ci/ml [33Slmethionine for 15 min. The medium was removed, cells were scraped from the culture dish, and protein in all samples was precipitated with trichloracetic acid, filtered, and counted.
affect the level of tPA in the culture medium (Table III) . Moreover, thrombin inactivated by hirudin did not affect tPA release. To determine whether the high-affinity active siteindependent thrombin receptors were involved in the increase of tPA release, thrombin was added to the cultures in the presence of excess amounts of DFP-thrombin (20) . DFPthrombin does not clot fibrinogen but binds to this set of thrombin receptors in a fashion identical to that of active thrombin (20) . Little increase in the level of TPA was observed when the cells were treated with DFP-thrombin at a concentration equivalent to 50 U/ml (Table III) . This amount of DFP-thrombin however did not interfere with the stimulation of tPA release by 1 U/ml of active thrombin. The 6-h delay that occurs between thrombin addition and enhanced tPA release suggests that the increase depends upon other metabolic events. To determine whether protein synthesis or RNA synthesis is involved in the stimulation of tPA release, cultures were treated with either cycloheximide or actinomycin D at various times after thrombin addition, and the amount of tPA present in the conditioned medium was determined (Table IV) . No tPA was detected when cycloheximide was added 4 h after thrombin treatment. The final tPA concentration, however, was 16 and 30% of uninhibited thrombin treated cultures when cycloheximide was added 6 and 8 h post-thrombin, respectively. Treatment with actinomycin D also resulted in low tPA levels when added 3 or 4 h after thrombin (Table IV) . However, little effect was noticed when RNA synthesis was stopped 6 h after thrombin addition and virtually no effect was detected when actinomycin D was added 8 h after thrombin. Whereas the concentration of tPA in culture medium may be accurately measured by radioimmunometric assay, measurement of tPA activity is more difficult. Because of the presence of fibrinolytic inhibitors in the culture medium and the association of tPA with this inhibitor, direct assay of tPA Confluent cultures were exposed to I U/ml thrombin and either cycloheximide or actinomycin D was added at the prescribed time. At 14 h culture medium was removed and tPA concentration was determined by radioimmunometric assay. Results are presented as a percentage of the tPA concentration in cultures treated with thrombin but not metabolic inhibitors and are the average of two experiments performed in duplicate.
activity is unsuitable. It has been demonstrated, however, that exposure of the tPA-inhibitor complex to 1% SDS for 30 min at 370C results in the appearance of fibrinolytic activity (10) .
When this SDS-induced activation of tPA is used in conjunction with SDS-PAGE (to separate fibrinolytic inhibitors from the tPA) followed by fibrin autography (to visualize tPA activity), changes in the level of tPA activity in endothelial cell culture medium can be measured. To determine the effect of thrombin treatment on tPA activity, dose-response experiments were performed by use of 0.001 to 10 U/ml thrombin and analysis of the conditioned medium for tPA activity (Fig. 4) . In agreement with the changes in antigen levels, increasing concentrations of thrombin produced a dose-dependent increase in tPA activity with what appears to be the maximum amount of activity obtained with 1 U/ml. The increase in tPA activity did not result from direct thrombin activation of the inhibitor bound tPA since conditioned medium removed from untreated cells and treated with 1 U/ml thrombin for 16 h did not demonstrate increased tPA activity (data not shown).
Discussion
The human endothelial cells. This stimulation is dependent, saturable, and active site depender to thrombin is delayed with a significant incr of release not occurring until 6 h after thrc Enhanced release continues for the next 10 declines. The thrombin effect does not appea high affinity, active site-independent thrombi on the endothelial cells, since prior exposure to of DFP-thrombin fail to inhibit increased tPh the mechanism of thrombin-mediated releaw that for arachidonate metabolites (21) and factor (6) .
Thrombin is intimately involved in th4 thrombi through its effect.on platelets (22) and formation (23 (Table IV) . Therefore, it appears as if RNA synthesis is necessary for increased release of tPA and the RNA involved is synthesized during the first 6-8 h after thrombin addition. The calcitonin-stimulated release of plasminogen activators from porcine renal tubular cells (24) and the increase in plasminogen activator production in human fibroblasts by a diffusible factor secreted by malignant murine cells (25) (6) . These studies indicated that the enhanced release of von Willebrand factor occurred within 30 min of thrombin addition and was complete in 6 h. Thus, thrombin regulation of tPA is independent of another major hemostatic protein.
The addition of thrombin to cultured bovine aortic endothelial cells has previously been shown to produce a rapid decrease in intracellular and secreted plasminogen activator activity (4). The differences in the results recorded for multiple passaged bovine cells and those reported here can be explained by the difference in the types of plasminogen activators produced. Bovine endothelial cells produce multiple forms of plasminogen activator, including both the tissue type and the urokinaselike (8) . Studies determining which of these forms was affected by thrombin addition revealed that the urokinase type was eliminated from the culture medium by thrombin treatment whereas the tPA did not appear to be affected (9) . Therefore the loss of the urokinase form was apparently responsible for the decline in plasminogen activator activity. Since primary cultures of human endothelial cells do not release urokinase no inhibitory effect was observed. Thus, the response of each of these cell types to thrombin differs substantially. Although the reason for this difference is not known, it may reflect independent regulatory mechanisms for the two endothelial cell-derived plasminogen activators.
The inhibitor-bound tPA that is present in the conditioned medium of cultured human endothelial cells (10) is probably not representative of the vascular tPA that is released from the endothelium. More likely, tPA-inhibitor complex formation follows release from the cells and is promoted in culture by in vitro conditions. This is supported by two observations: (a) The isolation of free tPA from plasma (29) indicates that the tPA released into the vasculature in vivo is free and available for fibrin binding and plasminogen activation. (b) A variety of normal and transformed human cell lines contain free tPA in their culture medium (30) . In certain cases both free and inhibitor-bound tPA are observed (8, 30) , suggesting that the tPA is released in its native state and becomes inhibitor bound in the extracellular environment. On the other hand, conditions favoring complex formation, which are present in cultures of human endothelial cells are: (a) the relatively high concentration of inhibitor in the culture medium, which is estimated to be at least 15 times the level of tPA (unpublished observation); (b) the length of the incubation period, which allows ample time for association to occur; and (c) the static condition of the cell culture system, which allows for maximum local concentration of both inhibitor and tPA with no means of continual clearance and separation of these molecules that might be affected by blood flow. In addition, the spontaneous formation of the bond (10) coupling the tPA to inhibitor and the irreversible nature of the interaction would tend to drive the reaction to completion over the times involved. Thus, although the lack of information about the fate of tPA in vivo makes it difficult to compare in vivo with in vitro events, we conclude that an increase in the level of tPA inhibitor complex as measured by the radioimmunometric assay represents an increase in the release of free tPA.
